Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, appointed    Florian Vogl, chief medical officer. Vogl assumes the CMO role from Frédéric Triebel, who previously acted as both chief scientific officer (CSO) and CMO of Immutep. Triebel will focus on his responsibilities as CSO and as a member of Immutep’s board of directors. Vogl brings over a decade of experience in the biopharmaceutical industry with e...